Despite a threefold increase in data collection over the last decade, the methods for cleaning and reconciling that data remain antiquated. Teams apply old, manual techniques to massive new datasets, creating major inefficiencies. The solution lies in applying automation and modern technology to data quality control, rather than throwing more people at the problem.
Related Insights
Instead of initiating daunting, multi-year data projects, the most practical first step to unifying customer profiles is to focus on fundamentals. Prioritize automated data integrations for list building and implement rigorous list cleaning and tracking from day one to avoid manual errors.
The primary barrier to deploying AI agents at scale isn't the models but poor data infrastructure. The vast majority of organizations have immature data systems—uncatalogued, siloed, or outdated—making them unprepared for advanced AI and setting them up for failure.
The conventional wisdom that enterprises are blocked by a lack of clean, accessible data is wrong. The true bottleneck is people and change management. Scrappy teams can derive significant value from existing, imperfect internal and public data; the real challenge is organizational inertia and process redesign.
A major hurdle for enterprise AI is messy, siloed data. A synergistic solution is emerging where AI software agents are used for the data engineering tasks of cleansing, normalization, and linking. This creates a powerful feedback loop where AI helps prepare the very data it needs to function effectively.
A critical error in AI integration is automating existing, often clunky, processes. Instead, companies should use AI as an opportunity to fundamentally rethink and redesign workflows from the ground up to achieve the desired outcome in a more efficient and customer-centric way.
While the FDA is often blamed for high trial costs, a major culprit is the consolidated Clinical Research Organization (CRO) market. These entrenched players lack incentives to adopt modern, cost-saving technologies, creating a structural bottleneck that prevents regulatory modernization from translating into cheaper and faster trials.
Many leaders hire ops personnel to "clean up the mess." However, without a strategic mandate to fix the root data architecture, these hires often get stuck in a perpetual cycle of data cleanup, reinforcing the broken, legacy system they were brought in to solve.
The primary reason multi-million dollar AI initiatives stall or fail is not the sophistication of the models, but the underlying data layer. Traditional data infrastructure creates delays in moving and duplicating information, preventing the real-time, comprehensive data access required for AI to deliver business value. The focus on algorithms misses this foundational roadblock.
Modernizing trials is less about new tools and more about adopting a risk-proportional mindset, as outlined in ICH E6(R3) guidelines. This involves focusing rigorous oversight on critical data and processes while applying lighter, more automated checks elsewhere, breaking the industry's habit of treating all data with the same level of manual scrutiny.
A shocking 30% of generative AI projects are abandoned after the proof-of-concept stage. The root cause isn't the AI's intelligence, but foundational issues like poor data quality, inadequate risk controls, and escalating costs, all of which stem from weak data management and infrastructure.
